Auditory late effects of chemotherapy

Cancer Treatment and Research

Volumn 150, Issue , 2009, Pages 195-213

  Meyer, Anna K ^a   Young, Nancy M ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; SODIUM THIOSULFATE; THIOSULFATE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; ANIMAL; ANIMAL MODEL; BRAIN TUMOR; CHILD; HEARING DISORDER; HUMAN; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; REVIEW; SKULL IRRADIATION; SURVIVOR; TIME;

ADOLESCENT; ADULT; AGE FACTORS; AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHILD; CRANIAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEARING DISORDERS; HUMANS; MODELS, ANIMAL; ORGANOPLATINUM COMPOUNDS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SURVIVORS; THIOSULFATES; TIME FACTORS; VINCRISTINE; YOUNG ADULT;

EID: 77956635711     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/b109924_13     Document Type: Article

References (115)

1. Fausti SA, Schechter MA, Rappaport BZ, et al. Early detection of cisplatin ototoxicity. Selected case reports. Cancer. 1984;53:224-231. (Pubitemid 14180732)
2. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649-655. (Pubitemid 39350398)
3. Kretschmar CS, Warren MP, Lavally BL, et al. Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol. 1990;8:1191-1198. (Pubitemid 20195629)
4. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006;107:417-422. (Pubitemid 44036572)
5. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40:2445-2451. (Pubitemid 39424959)
6. Skinner R, Pearson AD, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer. 1990;61:927-931. (Pubitemid 20197008)
7. Blakley BW, Myers SF. Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol Head Neck Surg. 1993;109:385-391. (Pubitemid 23318944)
8. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol. 1991;19:295-300.
9. Ilveskoski I, Saarinen UM, Wiklund T, et al. Ototoxicity in children with malignant brain tumors treated with the ''8 in 1'' chemotherapy protocol. Med Pediatr Oncol. 1996;27:26-31.
10. Montaguti M, Brandolini C, Ferri GG, et al.[Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention]. Acta Otorhinolaryngol Ital. 2002;22:14-18.
11. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatininduced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77:1355-1362. (Pubitemid 28140629)
12. Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatincontaining conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22:669-674. (Pubitemid 28486365)
13. Brown RL, Nuss RC, Patterson R, et al. Audiometric monitoring of cis-platinum ototoxicity. Gynecol Oncol. 1983;16:254-262. (Pubitemid 13014839)
14. Schaefer SD, Post JD, Close LG, et al. Ototoxicity of low- and moderate-dose cisplatin. Cancer. 1985;56:1934-1939. (Pubitemid 15240862)
15. Aguilar-Markulis NV, Beckley S, Priore R, et al. Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol. 1981;16:111-123. (Pubitemid 11125717)
16. Truong MT, Winzelberg J, Chang KW. Recovery from cisplatin-induced ototoxicity: a case report and review. Int J Pediatr Otorhinolaryngol. 2007;71:1631-1638. (Pubitemid 47368695)
17. Cohen BH, Zweidler P, Goldwein JW, et al. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg. 1990;16:292-296.
18. Freilich RJ, Kraus DH, Budnick AS, et al. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol. 1996;26:95-100. (Pubitemid 26010933)
19. Miettinen S, Laurikainen E, Johansson R, et al. Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol Suppl. 1997;529:90-94. (Pubitemid 27364367)
20. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989;7:754-760. (Pubitemid 19145597)
21. Simon T, Hero B, Dupuis W, et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr. 2002;214:149-152. (Pubitemid 34925488)
22. Canetta R, Rozencweig M, Carter SK. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985;12 Suppl A:125-136. (Pubitemid 16167909)
23. Meyers FJ, Welborn J, Lewis JP, et al. Infusion carboplatin treatment of relapsed and refractory acute leukemia: evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol. 1989;7:173-178. (Pubitemid 19048449)
24. Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children's Cancer Group. Cancer. 1994;73:1297-1301. (Pubitemid 24061630)
25. Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer. 2008;50:223-226.
26. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol. 2002;39:163-167. (Pubitemid 34827564)
27. Kennedy IC, Fitzharris BM, Colls BM, et al. Carboplatin is ototoxic. Cancer Chemother Pharmacol. 1990;26:232-234. (Pubitemid 20191203)
28. Allen JRL. Modern-period muddy sediments in the severn estuary (Southwestern UK) - A pollutant-based model for dating and correlation. Sedimentary Geol. 1988;58:1.
29. Macdonald MR, Harrison RV, Wake M, et al. Ototoxicity of carboplatin: comparing animal and clinical models at the Hospital for Sick Children. J Otolaryngol. 1994;23: 151-159. (Pubitemid 24238760)
30. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493-500. (Pubitemid 32707970)
31. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery. 1995;37:17-27; discussion -8.
32. Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut. 1990;61:320-321.
33. Aydogdu I, Ozturan O, Kuku I, et al. Bilateral transient hearing loss associated with vincristine therapy: case report. J Chemother. 2000;12:530-532. (Pubitemid 32048172)
34. Riga M, Psarommatis I, Korres S, et al. Neurotoxicity of vincristine on the medial olivocochlear bundle. Int J Pediatr Otorhinolaryngol. 2007;71:63-69. (Pubitemid 44959079)
35. Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol. 1983;12:365-369. (Pubitemid 14223103)
36. Boheim K, Bichler E. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol. 1985;242:1-6. (Pubitemid 15243649)
37. Komune S, Asakuma S, Snow JB, Jr. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg. 1981;89:275-282. (Pubitemid 11090690)
38. Hoistad DL, Ondrey FG, Mutlu C, et al. Histopathology of human temporal bone after cis-platinum, radiation, or both. Otolaryngol Head Neck Surg. 1998;118:825-832. (Pubitemid 28307471)
39. Hinojosa R, Riggs LC, Strauss M, et al. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol. 1995;16:731-740.
40. Dehne N, Lautermann J, Petrat F, et al. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol. 2001;174:27-34. (Pubitemid 32635003)
41. Takeno S, Harrison RV, Ibrahim D, et al. Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res. 1994;75:93-102. (Pubitemid 24141867)
42. Kwong DL, Wei WI, Sham JS, et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys.1996;36:281-289. (Pubitemid 26359451)
43. Walker DA, Pillow J, Waters KD, et al. Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol. 1989;17:48-52.
44. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-8596. (Pubitemid 46211500)
45. Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002;52:599-605. (Pubitemid 34158719)
46. Weatherly RA, Owens JJ, Catlin FI, et al. Cis-platinum ototoxicity in children. Laryngoscope. 1991;101:917-924.
47. McHaney VA TG, Hayes FA. Hearing loss in children receiving cisplatin chemotherapy. K Pediatr. 1983;83:314-317. (Pubitemid 13194726)
48. Pasic TR, Dobie RA. Cis-platinumototoxicity in children. Laryngoscope. 1991;101:985-991.
49. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006;24:918-924. (Pubitemid 46638845)
50. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756. (Pubitemid 19272848)
51. Peng B, English MW, Boddy AV, et al. Cisplatin pharmacokinetics in children with cancer. Eur J Cancer. 1997;33:1823-1828. (Pubitemid 28129211)
52. Peng B BA, English MW, et al. The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review. Anticancer Res. 1994;14:2279-2283.
53. Posner MR, Ferrari L, Belliveau JF, et al. A phase I trial of continuous infusion cisplatin. Cancer. 1987;59:15-18. (Pubitemid 17227387)
54. Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol. 2001;57:393-402. (Pubitemid 33787190)
55. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann N Y Acad Sci. 1999;884:15-18.
56. Dominici C, Petrucci F, Caroli S, et al. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J Clin Oncol. 1989;7:100-107. (Pubitemid 19089087)
57. Murakami T, Inoue S, Sasaki K, et al. Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Sel Cancer Ther. 1990;6:145-151.
58. Gupta AA, Capra M, Papaioannou V, et al. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors. J Pediatr Hematol Oncol. 2006;28:91-94.
59. Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, et al. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer. 2006;47:183-193. (Pubitemid 44025251)
60. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25:708-714. (Pubitemid 350002927)
61. Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11:639-643.
62. Kohn S, Fradis M, Podoshin L, et al. Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope. 1997;107:407-408. (Pubitemid 27147515)
63. Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355-360. (Pubitemid 46884215)
64. Hallmark RJ, Snyder JM, Jusenius K, et al. Factors influencing ototoxicity in ovarian cancer patients treated with Cis-platinum based chemotherapy. Eur J Gynaecol Oncol. 1992;13:35-44.
65. Gaegcnti DL. Childhood. In: Finegold M, Beningtion J, eds. Pathology of Neoplasia in Children and Adults. Philadelphia: WB Saunders. 1986:282-312.
66. Buhrer C, Weinel P, Sauter S, et al. Acute onset deafness in a 4-year-old girl after a single infusion of cis-platinum. Pediatr Hematol Oncol. 1990;7:145-148. (Pubitemid 20276761)
67. Berg AL, Spitzer JB, Garvin JH, Jr. Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope. 1999;109:1806-1814. (Pubitemid 29533925)
68. Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer. 2004;40:2352-2354. (Pubitemid 39424946)
69. Northern JL,Downs MP.Hearing inChildren, ed. Baltimore, MD:Williams&Wilkins, 1991
70. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 2004;35(Suppl 12):11-19.
71. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear. 1998;19:339-354. (Pubitemid 28465218)
72. Schmidt CM, Bartholomä us E, Deuster D, et al. The Muenster classification of high frequency hearing loss following cisplatin chemotherapy. HNO 2007;55(4):299-306.
73. Stavroulaki P, Apostolopoulos N, Segas J, et al. Evoked otoacoustic emissions - an approach for monitoring cisplatin induced ototoxicity in children. Int J Pediatr Otorhinolaryngol. 2001;59:47-57. (Pubitemid 32453343)
74. Littman TA, Magruder A, Strother DR. Monitoring and predicting ototoxic damage using distortion-product otoacoustic emissions: pediatric case study. J Am Acad Audiol. 1998;9:257-262.
75. Smith LJ, inventor Smith, L J (SMIT-Individual), assignee. Educational kit used for teaching paleontology to child. US. 1999 August 24.
76. Sockalingam R, Freeman S, Cherny TL, et al. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol. 2000;21:521-527. (Pubitemid 30432461)
77. Toral RM, Skurovitch-Bialik P, Collado-Corona MA, et al. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment. Arch Med Res. 2003;34:205-208. (Pubitemid 36870710)
78. Hotz MA, Harris FP, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope. 1994;104:1130-1134. (Pubitemid 24284721)
79. Subramaniam M, Salvi RJ, Spongr VP, et al. Changes in distortion product otoacoustic emissions and outer hair cells following interrupted noise exposures. Hear Res. 1994;74:204-216. (Pubitemid 24131284)
80. Dhooge I, Dhooge C, Geukens S, et al. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives. Int J Audiol. 2006;45:337-343. (Pubitemid 44576328)
81. Campbell KC, Kelly E, Targovnik N, et al. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol. 2003;14:157-168; quiz 70-71.
82. Ress BD, Sridhar KS, Balkany TJ, et al. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place - Resident Clinical Science Award. 1998. Otolaryngol Head Neck Surg. 1999;121: 693-701.
83. Knight KR, Kraemer DF, Winter C, et al. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol. 2007;25:1190-1195. (Pubitemid 46640564)
84. A. B. Room acoustics and speech perception. http://wwwwrohansdsuedu/- aboothro/ files/RoomAcoustics/Roomacousticsandspeechperceptionpdf, 2002.
85. Stelmachowicz PG, Pittman AL, Hoover BM, et al. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg. 2004;130:556-562. (Pubitemid 38609664)
86. Stelmachowicz PG, Pittman AL, Hoover BM, et al. Effect of stimulus bandwidth on the perception of /s/ in normal- and hearing-impaired children and adults. J Acoust Soc Am. 2001;110:2183-2190. (Pubitemid 32959716)
87. French NR, Steinberg J. Factors governing the intelligibility of speech sounds. J Acoust Soc Am. 1947;19:90-119.
88. Katz J WT. Introduction to the Handicap of Hearing Impairment: Auditory Impairment Versus Hearing Handicap.San Diego, CA: Singular Publishing Group; 1982.
89. Smoluk GD, Fahey RC, Calabro-Jones PM, et al. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res. 1988;48:3641-3647.
90. Schiller JH. High-dose cisplatin and vinblastine plus amifostine for metastatic non-small cell lung cancer. Semin Oncol. 1996;23:78-82. (Pubitemid 26321677)
91. Schuchter LM. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol). Eur J Cancer. 1996;32A Suppl 4:S40-S42.
92. Hospers GA, Eisenhauer EA, de Vries EG. The sulfhydryl containing compounds WR- 2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer. 1999;80:629-638. (Pubitemid 29209823)
93. Block KI GC. Commentary: the pharmacological antioxidant amifostine - implications of recent research for integrative cancer care. Integrative Cancer Therapies. 2005;4:325-351.
94. Hussain AE, Blakley BW, Nicolas M, et al. Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol. 2003;32:294-297. (Pubitemid 38175959)
95. Ekborn A, Hansson J, Ehrsson H, et al. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope. 2004;114:1660-1667. (Pubitemid 39278890)
96. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005;104:841-847. (Pubitemid 41113686)
97. Capizzi R. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol. 1996;23:2-17. (Pubitemid 26321666)
98. Neuwelt EA, Brummett RE, Remsen LG, et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res. 1996;56:706-709. (Pubitemid 26055456)
99. Neuwelt EA, Brummett RE, Doolittle ND, et al. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther. 1998;286: 77-84. (Pubitemid 28317976)
100. Abe R, Akiyoshi T, Tsuji H, et al. Protection of antiproliferative effect of cis-diamminedichloroplatinum (II) by sodium thiosulfate. Cancer Chemother Pharmacol. 1986;18: 98-100. (Pubitemid 17121419)
101. Elferink F, van der Vijgh WJ, Klein I, et al. Interaction of cisplatin and carboplatin withsodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986;32: 641-645. (Pubitemid 17027205)
102. Dickey DT, Wu YJ, Muldoon LL, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther. 2005;314:1052-1058. (Pubitemid 41205968)
103. Campbell KC, Rybak LP, Meech RP, et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90-98. (Pubitemid 26388984)
104. Reser D, Rho M, Dewan D, et al. L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology. 1999;20:731-748.
105. Korver KD, Rybak LP,Whitworth C, et al. Round window application ofD-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg. 2002;126: 683-689. (Pubitemid 41115249)
106. Campbell KC, Meech RP, Rybak LP, et al. D-Methionine protects against cisplatin damage to the stria vascularis. Hear Res. 1999;138:13-28.
107. Sequoia Ecosystem and Recreation Preserve Act of 1999. In. 106th Congress ed; 1999.
108. Wimmer C, Mees K, Stumpf P, et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol. 2004;25:33-40. (Pubitemid 39077568)
109. Church MW, Kaltenbach JA, Blakley BW, et al. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 1995;86:195-203.
110. Kaltenbach JA, Church MW, Blakley BW, et al. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg. 1997;117:493-500. (Pubitemid 27508141)
111. Copeland BJ, Pillsbury HC, 3rd. Cochlear implantation for the treatment of deafness. Annu Rev Med. 2004;55:157-167. (Pubitemid 38316720)
112. Brock P, Pritchard J, Bellman S, Pinkerton CR. Ototoxicity of high-dose cisplatinum in children. Med Pediatr Oncol.1988;16:368-369.
113. Brock P, Bellman S, Pritchard J. Ototoxicity of cisplatinum Br J Cancer.1991;63: 159-161.
114. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J. Cisplatin ototoxicity in children; a practical grading system. Med Pediatr Oncol.1991;19:295-300.
115. Brock P, Yeomans E, Bellman S, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer. 1992;66:Suppl XVIII:S36-S40.